Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.71 |
| ▸ | HBB | P68871 | 5/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | GMNN | O75496 | 1/20 | 0.71 |
| ▸ | PGR | P06401 | 1/20 | 0.71 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiamiprine SCHEMBL15284276 | 0.91 | MAPT (0.59) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL4436347 | 0.83 | MAPT (1.00) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL29693611 | 0.83 | MAPT (1.00) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL4278 | 0.83 | MAPT (1.00) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Thiamiprine SCHEMBL4852 | 0.82 | CYP1A2 (0.56) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Thiamiprine SCHEMBL29350246 | 0.82 | CYP1A2 (0.56) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL3089846 | 0.82 | MAPT (0.98) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL502599 | 0.82 | MAPT (0.98) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL26152 | 0.82 | MAPT (0.98) | MAPTHBBTP53SMN1; SMN2CYP3A4 | |
| Azathioprine SCHEMBL317904 | 0.82 | MAPT (0.98) | MAPTHBBTP53SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31597 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| EP-4698185-A1 | METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES | Osasuna Therapeutics SA (CH) | 2026-02-25 | — | — | EP | claimed |
| EP-4694909-A1 | METHODS OF MODULATING THE EPITHELIAL-MESENCHYMAL TRANSITION | RS Oncology, LLC (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2000061549-A2 | PHARMACEUTICAL COMPOUNDS | NICOX S.A. (FR) | 2000-10-19 | — | — | WO | claimed |
| WO-2000054795-A1 | COMBINED THERAPY WITH A CHEMOTHERAPEUTIC AGENT AND AN ONCOLYTIC VIRUS FOR KILLING TUMOR CELLS IN A SUBJECT | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-09-21 | — | — | WO | claimed |
| US-6121245-A | ADMINISTERING CHEMOTHERAPEUTIC AGENT AND SHARK LIVER OIL | FIRSHEIN RICHARD N (US) | 2000-09-19 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0577215-B1 | Process for obtaining surface modified anticancer nanoparticles | NANOSYSTEMS LLC (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1999058126-B1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | ENDOWMENT RES INHUMAN BIOLOGY (US) | 2000-02-17 | — | — | WO | claimed |
| WO-1999058126-A1 | USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| EP-0641193-A4 | CHEMOTHERAPEUTIC DRUG COMBINATIONS. | MARTIN DANIEL S (US) | 1995-09-06 | — | — | EP | claimed |
| EP-0641193-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | PRO-NEURON, INC. (US) | 1995-03-08 | — | — | EP | claimed |
| WO-1993023014-A1 | CHEMOTHERAPEUTIC DRUG COMBINATIONS | MARTIN DANIEL S (US) | 1993-11-25 | — | — | WO | claimed |